MX2021006011A - Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. - Google Patents
Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.Info
- Publication number
- MX2021006011A MX2021006011A MX2021006011A MX2021006011A MX2021006011A MX 2021006011 A MX2021006011 A MX 2021006011A MX 2021006011 A MX2021006011 A MX 2021006011A MX 2021006011 A MX2021006011 A MX 2021006011A MX 2021006011 A MX2021006011 A MX 2021006011A
- Authority
- MX
- Mexico
- Prior art keywords
- aurora
- neuroblastoma
- treatment
- kinase inhibitor
- kinase
- Prior art date
Links
- 102000004000 Aurora Kinase A Human genes 0.000 title abstract 2
- 108090000461 Aurora Kinase A Proteins 0.000 title abstract 2
- 206010029260 Neuroblastoma Diseases 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona un inhibidor de la quinasa Aurora A que se ilustra a continuación, (ver Fórmula) o una sal aceptable desde el punto de vista farmacéutico de este, para su uso en el tratamiento del neuroblastoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773367P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/062718 WO2020112514A1 (en) | 2018-11-30 | 2019-11-22 | An aurora a kinase inhibitor for use in the treatment of neuroblastoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006011A true MX2021006011A (es) | 2021-09-21 |
Family
ID=68916597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006011A MX2021006011A (es) | 2018-11-30 | 2019-11-22 | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220000855A1 (es) |
| EP (1) | EP3886855A1 (es) |
| JP (2) | JP2022508183A (es) |
| KR (1) | KR20210084555A (es) |
| CN (1) | CN113038950A (es) |
| AU (1) | AU2019388843B2 (es) |
| BR (1) | BR112021006578A2 (es) |
| CA (1) | CA3121483A1 (es) |
| EA (1) | EA202191051A1 (es) |
| IL (1) | IL282270A (es) |
| MA (1) | MA54290A (es) |
| MX (1) | MX2021006011A (es) |
| SG (1) | SG11202104344RA (es) |
| UA (1) | UA125892C2 (es) |
| WO (1) | WO2020112514A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI785474B (zh) * | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| TW202321215A (zh) * | 2021-07-28 | 2023-06-01 | 大陸商北京加科思新藥研發有限公司 | Aurora a 選擇性抑制劑的多晶型及其用途 |
| CA3247183A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN119909190B (zh) * | 2025-02-10 | 2025-09-30 | 首都医科大学附属北京儿童医院 | Aurora A抑制剂和LUBAC抑制剂联合使用在制备治疗神经母细胞瘤药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9576309B2 (en) | 2014-11-12 | 2017-02-21 | Snergy Inc. | Dynamic power sharing system and map view graphical user interface |
| TWI693218B (zh) * | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
-
2019
- 2019-11-22 MA MA054290A patent/MA54290A/fr unknown
- 2019-11-22 AU AU2019388843A patent/AU2019388843B2/en not_active Ceased
- 2019-11-22 JP JP2021529009A patent/JP2022508183A/ja active Pending
- 2019-11-22 UA UAA202101953A patent/UA125892C2/uk unknown
- 2019-11-22 EA EA202191051A patent/EA202191051A1/ru unknown
- 2019-11-22 EP EP19821387.8A patent/EP3886855A1/en not_active Withdrawn
- 2019-11-22 MX MX2021006011A patent/MX2021006011A/es unknown
- 2019-11-22 BR BR112021006578-4A patent/BR112021006578A2/pt not_active IP Right Cessation
- 2019-11-22 KR KR1020217015919A patent/KR20210084555A/ko not_active Ceased
- 2019-11-22 SG SG11202104344RA patent/SG11202104344RA/en unknown
- 2019-11-22 WO PCT/US2019/062718 patent/WO2020112514A1/en not_active Ceased
- 2019-11-22 CN CN201980077760.3A patent/CN113038950A/zh active Pending
- 2019-11-22 US US17/295,721 patent/US20220000855A1/en not_active Abandoned
- 2019-11-22 CA CA3121483A patent/CA3121483A1/en active Pending
-
2021
- 2021-04-12 IL IL282270A patent/IL282270A/en unknown
-
2023
- 2023-02-07 JP JP2023016982A patent/JP2023058582A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019388843B2 (en) | 2023-03-23 |
| AU2019388843A1 (en) | 2021-05-20 |
| KR20210084555A (ko) | 2021-07-07 |
| SG11202104344RA (en) | 2021-05-28 |
| EA202191051A1 (ru) | 2021-08-26 |
| CN113038950A (zh) | 2021-06-25 |
| UA125892C2 (uk) | 2022-06-29 |
| WO2020112514A1 (en) | 2020-06-04 |
| JP2023058582A (ja) | 2023-04-25 |
| US20220000855A1 (en) | 2022-01-06 |
| IL282270A (en) | 2021-05-31 |
| EP3886855A1 (en) | 2021-10-06 |
| MA54290A (fr) | 2022-03-09 |
| CA3121483A1 (en) | 2020-06-04 |
| BR112021006578A2 (pt) | 2021-07-27 |
| JP2022508183A (ja) | 2022-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| ZA202202097B (en) | Amino pyrimidine ssao inhibitors | |
| NZ763551A (en) | Compounds useful for inhibiting cdk7 | |
| EA201890318A1 (ru) | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
| MY205416A (en) | Tyk2 inhibitors and uses thereof | |
| PH12019500775A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| SA520412335B1 (ar) | مشتقات أوكسي فلورو ببريدين كمثبط كيناز | |
| NZ752250A (en) | Compounds, devices, and uses thereof | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
| PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
| UA118149C2 (uk) | Інгібітор jak | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| NZ730771A (en) | Aurora a kinase inhibitor | |
| PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MX2022007626A (es) | Combinaciones. | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| NZ790037A (en) | Combinations | |
| MX2024010644A (es) | Uso de iptacopan para el tratamiento de la nefritis lupica. | |
| PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
| MX2020008273A (es) | Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos. |